SensiQ, Inventiva Set Up a European SPR Center of Excellence
News Feb 14, 2015
SensiQ and Inventiva have announced the launch of a European Center of Excellence in SPR technologies, using SensiQ® Pioneer Fragment Edition (Pioneer FE) instrumentation.
The SPR Center of Excellence is based in Dijon, France. Inventiva’s existing pharmaceutical discovery platform will now include SensiQ SPR technology, which strengthens Inventiva’s current service offering.
The new Center also allows SensiQ to offer prospective customers on-site demonstrations at Inventiva’s offices. Inventiva’s entire team will benefit from the extensive SPR experience from the SensiQ dedicated support staff.
“The Center of Excellence will provide additional technological capabilities to our partners. It also enhances our extensive HTS and HCS screening platforms, which, combined with our proprietary library, provide one of the most compelling offerings available on the market”, said Frederic Cren, co-founder and CEO of Inventiva. “We look forward to using the SensiQ Pioneer equipment. It provides us with a powerful tool to measure binding interactions and accelerate drug discovery for our partners”, said Pierre Broqua, co-founder and CSO of Inventiva.
“The newly released Pioneer FE represents a new paradigm in capability and performance. We are thrilled that Inventiva has chosen to make it the centerpiece of the SPR Center of Excellence in Dijon”, said Colin Cumming, CEO of SensiQ.
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE
Brian Berridge Set to Manage National Toxicology ProgramNews
The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.READ MORE
Researchers Identify Druggable Genomic Targets in Malaria ParasiteNews
Using whole-genome analysis and chemogenomics, scientists have discovered novel antimalarial drug targets and drug-resistance genes. The researchers analyzed >250 Plasmodium falciparum cell lines, which were resistant to 37 different anti-malarial compounds.READ MORE